Please login to the form below

Not currently logged in
Email:
Password:

Flutiform

This page shows the latest Flutiform news and features for those working in and with pharma, biotech and healthcare.

Vectura's Flutiform flunks phase III COPD test

Vectura's Flutiform flunks phase III COPD test

Vectura's hopes of extending the uses of its asthma drug Flutiform into chronic obstructive pulmonary disease (COPD) have been dashed by disappointing phase III data. ... Flutiform sales doubled last year to reach 144m in 2015, and in the first six

Latest news

  • Vectura to merge with SkyePharma in £441m deal Vectura to merge with SkyePharma in £441m deal

    SkyePharma has just reported record revenues for 2015 of £95m, up 30% with the help of rising royalties and product supply fees for asthma therapy Flutiform (fluticasone/formoterol) and GlaxoSmithKline's

  • Successful partnerships in pharma: Skyepharma and Mundipharma Successful partnerships in pharma: Skyepharma and Mundipharma

    Why skills and flexibility matter more than sheer size. Skyepharma and Mundipharma collaborated on the respiratory drug Flutiform. ... was able to make decisions quickly and was equally committed to the success of Flutiform.

  • Double asthma approval in Japan lifts SkyePharma Double asthma approval in Japan lifts SkyePharma

    The Japanese Ministry of Health, Labour and Welfare (MHLW) cleared GlaxoSmithKline's (GSK) Relvar Ellipta (vilanterol and fluticasone), as well as Kyorin Pharmaceutical's Flutiform (formoterol and fluticasone) for the treatment ... Meanwhile, the

  • Portland Health wins Mundipharma account

    High on the Portland Health's agenda will be to raise the profile of the recently launched asthma drug Flutiform (fluticasone/formoterol).

  • Pharma news in brief

    Our weekly round-up of news affecting the industry. SkyePharma signs key Flutiform marketing deal. ... SkyePharma has finally signed a US marketing agreement for its key asthma treatment, Flutiform, with Kos Pharmaceuticals, a deal which could be worth

More from news
Approximately 2 fully matching, plus 24 partially matching documents found.

Latest Intelligence

  • Interview: Georg Toufar, Mundipharma Interview: Georg Toufar, Mundipharma

    Treatments successfully brought to market in this way include asthma treatment Flutiform, created by Skye Pharma, and restless legs syndrome treatment Targin.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
mXm Medical Communications

mXm Medical Communications meets the needs of pharmaceutical marketers and medics who require a highly experienced, bespoke service from their...

Latest intelligence

The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....
Escaping the spin cycle of sub-optimal launch
...

Infographics